



DUOPHARMA

**DUOPHARMA BIOTECH BERHAD**

Registration No: 200001021664 (524271-W)

(Incorporated in Malaysia)

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME  
FOR THE PERIOD ENDED 30 SEPTEMBER 2024**

	INDIVIDUAL PERIOD		CUMULATIVE PERIOD	
	CURRENT YEAR QUARTER 30/9/2024 RM'000	PRECEDING YEAR CORRESPONDING QUARTER 30/9/2023 RM'000	CURRENT YEAR TO DATE 30/9/2024 RM'000	PRECEDING YEAR CORRESPONDING PERIOD 30/9/2023 RM'000
Revenue	208,732	169,235	620,024	537,226
Cost of Sales	(131,942)	(104,760)	(394,025)	(324,344)
<b>Gross Profit</b>	<b>76,790</b>	<b>64,475</b>	<b>225,999</b>	<b>212,882</b>
Other operating income	393	17	507	83
Distribution costs	(29,437)	(26,375)	(85,173)	(79,682)
Administration expenses	(21,529)	(18,889)	(61,727)	(62,271)
Other operating expenses	(174)	(2,535)	(799)	(3,321)
<b>Profit from operations</b>	<b>26,043</b>	<b>16,693</b>	<b>78,807</b>	<b>67,691</b>
Finance income	1,445	392	4,530	1,328
Finance costs	(6,968)	(5,658)	(20,756)	(12,786)
<b>Profit before taxation</b>	<b>20,520</b>	<b>11,427</b>	<b>62,581</b>	<b>56,233</b>
Taxation	(4,925)	(2,457)	(15,019)	(12,090)
<b>Profit after tax for the period</b>	<b>15,595</b>	<b>8,970</b>	<b>47,562</b>	<b>44,143</b>
<b>Other comprehensive income</b>				
Fair value of available-for-sale financial assets	(4,225)	(3,816)	(12,682)	(15,781)
Foreign currency translation differences for foreign operations	346	272	980	(213)
<b>Total other comprehensive income for the period</b>	<b>11,716</b>	<b>5,426</b>	<b>35,860</b>	<b>28,149</b>
<b>Profit attributable to:</b>				
Shareholders of the Company	15,595	8,970	47,562	44,143
Minority interest	-	-	-	-
	<b>15,595</b>	<b>8,970</b>	<b>47,562</b>	<b>44,143</b>
<b>Total comprehensive income attributable to:</b>				
Shareholders of the Company	11,716	5,426	35,860	28,149
Minority interest	-	-	-	-
	<b>11,716</b>	<b>5,426</b>	<b>35,860</b>	<b>28,149</b>
Earnings per share (sen)				
Basic (based on weighted average)	1.62	0.93	4.94	4.61
Diluted (based on weighted average)	1.62	0.93	4.94	4.61

(The Condensed Consolidated Income Statement should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2023 and the accompanying explanatory notes attached to the interim financial statements.)



**DUOPHARMA BIOTECH BERHAD**

Registration No: 200001021664 (524271-W)

(Incorporated in Malaysia)

**CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION  
AS AT 30 SEPTEMBER 2024**

	UNAUDITED AS AT 30/9/2024 RM'000	AUDITED AS AT 31/12/2023 RM'000
<b>ASSETS</b>		
Property, Plant and Equipment	557,854	582,365
Investment property	1,050	1,050
Intangible assets	36,995	38,802
Other investments	24,225	36,907
Deferred Tax Assets	7,515	8,946
<b>Total non-current assets</b>	<u>627,639</u>	<u>668,070</u>
Inventories	219,965	243,068
Current Tax Assets	21,234	16,320
Trade & Other Receivables	223,672	147,175
Cash & Cash Equivalents	260,423	270,502
<b>Total current assets</b>	<u>725,294</u>	<u>677,065</u>
<b>Total Assets</b>	<u><b>1,352,933</b></u>	<u><b>1,345,135</b></u>
<b>EQUITY</b>		
Share Capital	432,466	432,466
Reserves	(76,110)	(64,408)
Retained earnings	339,693	319,065
<b>Total Equity</b>	<u>696,049</u>	<u>687,123</u>
<b>LIABILITIES</b>		
Borrowings	468,678	480,902
Trade & Other Payables	2,915	1,476
Deferred Tax Liability	17,730	8,906
<b>Total non-current liabilities</b>	<u>489,323</u>	<u>491,284</u>
Borrowings	55,820	65,546
Trade & Other Payables	109,822	100,815
Current Tax Liabilities	1,919	367
<b>Total current liabilities</b>	<u>167,561</u>	<u>166,728</u>
<b>Total Liabilities</b>	<u><b>656,884</b></u>	<u><b>658,012</b></u>
<b>Total Equity &amp; Liabilities</b>	<u><b>1,352,933</b></u>	<u><b>1,345,135</b></u>
<b>Net assets per share (RM)</b>	<b>0.72</b>	<b>0.71</b>

(The Condensed Consolidated Balance Sheet should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2023 and the accompanying explanatory notes attached to the interim financial statements.)



**DUOPHARMA BIOTECH BERHAD**

**Registration No: 200001021664 (524271-W)**

(Incorporated in Malaysia)

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY  
FOR THE PERIOD ENDED 30 SEPTEMBER 2024**

Group	Non-distributable			Distributable	
	Share Capital RM '000	Translation Reserve RM '000	Fair value Reserve RM '000	Retained Profit RM '000	Total RM '000
At 1 January 2024	432,466	583	(64,991)	319,065	687,123
Foreign currency translation differences for foreign operations	-	980	-	-	980
Net change in fair value of equity instrument designated at FVOCI	-	-	(12,682)	-	(12,682)
Profit for the period	-	-	-	47,562	47,562
Profit and total comprehensive income for the period	-	980	(12,682)	47,562	35,860
2023 Second Interim Dividend ( 1.8 sen )	-	-	-	(17,315)	(17,315)
2024 First Interim Dividend ( 1.0 sen)	-	-	-	(9,619)	(9,619)
At 30 September 2024	432,466	1,563	(77,673)	339,693	696,049

Group	Non-distributable			Distributable	
	Share Capital RM '000	Translation Reserve RM '000	Fair value Reserve RM '000	Retained Profit RM '000	Total RM '000
At 1 January 2023	419,367	811	(53,326)	288,370	655,222
Foreign currency translation differences for foreign operations	-	(228)	-	-	(228)
Net change in fair value of equity instrument designated at FVOCI	-	-	(11,665)	-	(11,665)
Profit for the period	-	-	-	52,645	52,645
Profit and total comprehensive income for the year	-	(228)	(11,665)	52,645	40,752
Issuance of 9,702,761 new shares pursuant to Dividend Reinvestment Plan	13,099	-	-	-	13,099
2022 Second Interim Dividend ( 1.8 sen )	-	-	-	(17,140)	(17,140)
2023 First Interim Dividend ( 0.5 sen)	-	-	-	(4,810)	(4,810)
At 31 December 2023	432,466	583	(64,991)	319,065	687,123

(The Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2023 and the accompanying explanatory notes attached to the interim financial statements.)



DUOPHARMA

**DUOPHARMA BIOTECH BERHAD**

Registration No: 200001021664 (524271-W)

(Incorporated in Malaysia)

**UNAUDITED CONDENSED CONSOLIDATED CASH FLOW STATEMENT  
FOR THE PERIOD ENDED 30 SEPTEMBER 2024**

	30 SEPTEMBER 2024	30 SEPTEMBER 2023
	RM '000	RM '000
<b>Cash flows from operating activities</b>		
Profit before taxation	62,581	56,233
Adjustments for:		
Depreciation of property, plant and equipment	30,129	26,879
Amortisation of intangible asset	3,606	2,298
Finance income from		
- Cash and cash equivalents	(4,530)	(1,328)
Impairment of inventories	6,317	4,347
Write off on property, plant and equipment	-	2,425
Finance costs	20,756	12,786
(Reversal)/Impairment loss on trade receivables	(1,014)	2,952
Net unrealised foreign exchange (gain)/loss	202	1,029
Gain on disposal of PPE	(395)	-
<i>Operating profit before changes in working capital</i>	<u>117,652</u>	<u>107,621</u>
Change in inventories	16,786	(21,561)
Change in receivables, deposits and prepayments	(64,493)	(27,099)
Change in payables and accruals	9,085	(23,305)
<i>Cash generated from operations</i>	<u>79,030</u>	<u>35,656</u>
Finance costs paid	(20,593)	(15,465)
Net income tax paid	(8,126)	(14,699)
Net cash from operating activities	<u>50,311</u>	<u>5,492</u>
<b>Cash flows from investing activities</b>		
Acquisition of property, plant and equipment	(14,476)	(23,944)
Acquisition of other investments	-	(6,421)
Proceed from disposal of property, plant and equipment	501	-
Acquisition of intangible assets	(1,799)	(2,445)
Interest received from		
- Cash and cash equivalents	4,530	1,328
Net cash used in investing activities	<u>(11,244)</u>	<u>(31,482)</u>
<b>Cash flows from financing activities</b>		
Drawdown of borrowings	69,490	426,513
Repayment of borrowings	(91,603)	(266,622)
Dividends paid to shareholders of the Company	(26,934)	(8,851)
Payment of lease liabilities	(1,079)	(590)
Net cash (used in)/from financing activities	<u>(50,126)</u>	<u>150,450</u>
Net decrease/(increase) in cash and cash equivalents	(11,059)	124,460
Exchange differences on translation of financial statement of foreign operations	980	(213)
Cash and cash equivalents at 1 January	270,502	157,637
Cash and cash equivalents as at 30 September	<u><u>260,423</u></u>	<u><u>281,884</u></u>

(l) Cash and cash equivalents comprise:

	RM '000	RM '000
Deposits placed with licensed banks	10,000	10,860
Cash and bank balances	97,694	89,409
Highly liquid investment with financial institutions	152,729	181,615
	<u>260,423</u>	<u>281,884</u>

(The Condensed Consolidated Cash Flow Statement should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2023 and the accompanying explanatory notes attached to the interim financial statements.)



DUOPHARMA

**DUOPHARMA BIOTECH BERHAD**

**Registration No: 200001021664 (524271-W)**

(Incorporated in Malaysia)

**Quarterly Report On Results For The Period Ended 30 September 2024**

**NOTES TO INTERIM FINANCIAL REPORT**

**A1 Accounting Policies and Method of Computation**

The interim financial statements are unaudited and have been prepared in accordance with the applicable disclosure provisions of the Listing Requirements of the Bursa Malaysia Securities Berhad, MFRS 134: *Interim Financial Reporting* and with IAS 34, *Interim Financial Reporting*.

These interim financial statements should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2023 and the explanatory notes attached to the interim financial statements.

The following MFRSs and Amendments to MFRSs applicable to the Group have been adopted with effect from 1 January 2024 :

**MFRSs, interpretations and amendments effective for annual periods beginning on or after 1 January 2024**

- Amendments to MFRS 16, *Leases – Lease Liability in a Sale and Leaseback*
- Amendments to MFRS 101, *Presentation of Financial Statements – Non-current Liabilities with Covenants and Classification of Liabilities as Current or Non-current*
- Amendments to MFRS 107, *Statement of Cash Flows* and MFRS 7, *Financial Instruments: Disclosures – Supplier Finance Arrangements*

The following are accounting standards, amendments and interpretations that have been issued by the Malaysian Accounting Standards Board ("MASB") but have not been adopted by the Group:

**MFRSs, interpretations and amendments effective for annual periods beginning on or after 1 January 2025**

- Amendments to MFRS 121, *The Effects of Changes in Foreign Exchange Rates – Lack of Exchangeability*

**MFRSs, interpretations and amendments effective for annual periods beginning on or after 1 January 2026**

- Amendments to MFRS 9, *Financial Instruments* and MFRS 7, *Financial Instruments: Disclosures – Classification and Measurement of Financial Instruments*

**MFRSs, interpretations and amendments effective for annual periods beginning on or after 1 January 2027**

- MFRS 18, *Presentation and Disclosure in Financial Statements*
- MFRS 19, *Subsidiaries without Public Accountability: Disclosures*

**MFRSs, Interpretations and amendments effective for annual periods beginning on or after a date yet to be confirmed**

- Amendments to MFRS 10, *Consolidated Financial Statements* and MFRS 128, *Investments in Associates and Joint Ventures – Sale or Contribution of Assets between an Investor and its Associate or Joint Venture*

The initial application of the above pronouncements did not have any material impact to the consolidated financial statements of the Group.

**A2 Audit Report**

The audited report of the Company's preceding annual financial statements was not qualified.

**A3 Seasonal or Cyclical Factors**

The Group's sales typically peak in the first three quarters of the calendar year with higher demand in the public health sector and will gradually taper off in the final quarter of the calendar year.

**A4 Exceptional/Extraordinary Items**

There were no exceptional/extraordinary items for the financial year under review.

**A5 Changes in Estimates**

There was no change in estimates that have a material effect in the current quarter results.

**A6 Debts and Equity Securities**

There were no issuance and/or repayment of debt and equity securities, share buy-backs, share cancellations, shares held as treasury shares and resale of treasury shares in the current financial period.

**A7 Dividend Paid**

The Group paid an interim dividend of 1.0 sen per share (2023: first interim dividend of 0.5 sen per share) equivalent to RM9.62 million (2023:RM 4.81 million) in respect of financial year ending 31 December 2024 during the current quarter.

**A8 Segment Information**

	Quarter Ended		Year To Date	
	30/9/2024		30/9/2024	
	RM ' 000		RM ' 000	
Sales by operating sector :-	Sales	Gross Profit	Sales	Gross Profit
Local	197,114	73,476	578,411	212,939
Export	11,618	3,314	41,613	13,060
	208,732	76,790	620,024	225,999

**A9 Post Balance Sheet Events**

There are no material events after the year ended up to 1 November 2024 (latest practicable date which is not earlier than 7 days from the date of issuance of this quarterly report) that have not been reflected in the financial statements for the financial period ended 30 September 2024.

**A10 Changes in the Composition of the Group**

There was no changes in the composition of the Group for the period under review.

## ADDITIONAL INFORMATION REQUIRED BY BURSA SECURITIES LISTING REQUIREMENTS

### B1 Review of Performance

	Year To Date (30/9/24) RM'000	Year To Date (30/9/23) RM'000	Variance	
			RM'000	%
Revenue	620,024	537,226	82,798	15.4
Profit before tax (PBT)	62,581	56,233	6,348	11.3
Profit after tax (PAT)	47,562	44,143	3,419	7.7

For the current period ended 30 September 2024, the Group achieved a revenue of RM620.02 million, marking a 15.4% increase compared to RM537.23 million in the corresponding period last year. This robust double-digit growth was primarily driven by higher sales across overall key sectors, particularly public health segment.

The growth in revenue led to increase in PBT albeit at slightly lower pace due to the increase in operational costs associated with the newly completed K3 facility and higher finance costs.

### B2 Comparison with the Preceding Quarter's Results

	Qtr 3 2024 (30/9/24) RM'000	Qtr 2 2024 (30/6/24) RM'000	Variance	
			RM'000	%
Revenue	208,732	218,324	(9,592)	(4.4)
Profit before tax (PBT)	20,520	21,960	(1,440)	(6.6)
Profit after tax (PAT)	15,595	16,689	(1,094)	(6.6)

The Group reported a revenue of RM208.73 million for the current quarter ended 30 September 2024, which is marginally lower as compared to the record breaking sales of RM218.32 million recorded in the preceding quarter mainly due to lower sales to the prescription market. Lower revenue for the quarter also resulted in a lower PBT compared to the preceding quarter.

### B3 Prospects for the Remainder of Current Financial Year

According to the World Bank's October 2024 Malaysia Economic Monitor Report, Malaysia's economy is projected to expand at a faster pace in 2024, following a period of weaker-than-expected growth last year. Strong economic momentum in the first half of 2024 has been driven by robust private consumption, higher investment levels buoyed by increased FDI inflows, and an improvement in export performance. The World Bank now forecasts Malaysia's GDP to grow by 4.9% in 2024, a 0.6 percentage point increase from the previous estimate of 4.3% made in April.

Furthermore, the recently announced Malaysia Budget 2025 allocates RM45.27 billion to the Ministry of Health (MOH), marking an approximately 10% increase from the RM41.20 billion allocated in 2024. This significant increase reflects the government's strong commitment to comprehensively reforming public healthcare services and enhancing the well-being of the population. The MOH's initiatives are expected to drive continued demand for medical supplies and create opportunities for pharmaceutical market players to benefit from increased healthcare investments. The following developments also augur well for the overall business of Duopharma Group:

a) The Government of Malaysia had accepted the tender offer from Duopharma Marketing Sdn. Bhd. ("DMktg") (a wholly-owned subsidiary of Duopharma Biotech Berhad) and Biocon Sdn. Bhd. ("Biocon") to supply Insugen-Insulin Recombinant Human Formulations (hereinafter referred to as the "Products") under the Ministry of Health's ("MOH") procurement for a period of three (3) years commencing on 29 April 2022 until 28 April 2025 with a total contract value of RM375 million (hereinafter referred to as the "Revised Letter of Award"). DMktg and Biocon have acknowledged receipt and acceptance of the Revised Letter of Award on 25 April 2022 and submitted the same to the Ministry of Health on 25 April 2022. The supply of the Products to the Government of Malaysia has already commenced. Pursuant to the Revised Letter of Award, the formal agreement for the procurement via direct negotiation for the supply of insulin medicine as a package ('Perjanjian Perolehan Secara Rundingan Terus Pembekalan Ubat Insulin Secara Pakej') between the Government of Malaysia, DMktg as the Supplier/Distributor and Biocon as the manufacturer has been executed on 30 September 2022.

b) Per the Company's announcement made on 30 April 2024, Duopharma (M) Sendirian Berhad and Duopharma Manufacturing (Bangi) Sdn. Bhd., both the wholly-owned subsidiaries of the Company, have received and accepted seven (7) and four (4) Letters of Offer ("LOO"), respectively, from Pharnaniaga Logistics Sdn. Bhd. (hereinafter referred to as the "Customer") for the supply of pharmaceutical and/or non-pharmaceutical products as set out in the respective LOOs (hereinafter referred to as "Products") to the offices and facilities operated and controlled by the Government of Malaysia, through the Customer (hereinafter referred to as the "Contract(s)"). All the Contract(s) shall remain valid and binding until 31 December 2026 or such other date as directed by the Government of Malaysia. The total number of Products in aggregate to be supplied under all the aforementioned Contract(s) is 86 and the total estimated value in aggregate of all the aforementioned Contract(s) is approximately RM578,093,475.72 for the duration of the Contract(s) until 31 December 2026.

In addition to the abovementioned Contract(s), Duopharma (M) Sendirian Berhad and Duopharma Manufacturing (Bangi) Sdn. Bhd., have received and accepted additional four (4) and one (1) LOO, respectively, from the Customer for the supply of pharmaceutical and/or non-pharmaceutical products as set out in the respective LOO to the offices and facilities operated and controlled by the Government of Malaysia, through the Customer (hereinafter referred to as the "Additional Contract(s)"). All the Additional Contract(s) shall remain valid and binding until 31 December 2026 or such other date as directed by the Government of Malaysia. The total number of Products in aggregate to be supplied under all the Additional Contract(s) is 10 and the total estimated value in aggregate of all the Additional Contract(s) is approximately RM87,663,323.60 for the duration of the Additional Contract(s).

The total number of Products in aggregate to be supplied under all the abovementioned Contract(s) plus the Additional Contract(s) is 96 and the total estimated value in aggregate of all the abovementioned Contract(s) plus the Additional Contract(s) is approximately RM665,756,799.32 for the duration of the Contract(s) and the Additional Contract(s).

The Group anticipates continued challenges from elevated electricity tariffs, higher interest rates, and inflationary pressures, all of which strain manufacturing margins and overall profitability. However, the trend of Active Pharmaceutical Ingredient (API) prices normalizing to pre-pandemic levels is expected to provide some relief, cushioning the impact of rising operational costs. Despite these headwinds, the Group remains committed to enhancing internal efficiencies and cost-management strategies to mitigate the impact of increasing operational and financial costs.

The acceptance of new supply agreements with Pharmaniaga Logistic Sdn. Bhd. strengthens the Group's positioning for a satisfactory performance in 2024. Additionally, the recent strengthening of the Ringgit Malaysia against US Dollar, if persisting, may augur well for the Group's profitability over the longer term. With a focus on a sustainable growth, the Group remains cautiously optimistic, barring any unforeseen market changes or developments.

**B4 Profit Forecast**

No commentary is made on any variance between actual profit from forecast profit as it does not apply to the Group.

**B5 Taxation**

Details of taxation are as follows :-

	<b>Current Year Quarter 30/9/24 RM'000</b>	<b>Current Year To Date 30/9/24 RM'000</b>
Based on results for the quarter/year	(2,455)	(4,764)
Transfer (from)/to deferred tax	(2,470)	(10,255)
	(4,925)	(15,019)

The Group's tax expense is recognised in each financial quarter based on the best estimate of the expected annual effective tax rate for the full financial year.

**B6 Unquoted Investments and Properties**

Duopharma Marketing Sdn. Bhd., (a wholly-owned subsidiary of Duopharma Biotech Berhad) had on 16 April 2024 entered into a Sale & Purchase Agreement ("SPA") with Plastictecnic (M) Sdn. Bhd ("the Purchaser") for the disposal of four apartment units ("Properties") in Bandar Baru Bangi, Hulu Langat, Selangor for a sale consideration of RM480,000.00 ("Disposal Price"). The Disposal Price was arrived at on a willing-buyer willing-seller basis, based on negotiation between the Parties and after taking into consideration the market value of the Properties by comparing the Properties with similar properties that were either transacted recently or listed for sale within the same location or other comparable localities.

The sale of the Properties has been completed on 6 August 2024.

**B7 Status of Corporate Proposals**

On 29 September 2023 and 15 December 2023, Duopharma Biotech made its Sukuk Wakalah issuance of RM364.0 million and RM29.0 million respectively, for tenures between 3 – 10 years under the Sukuk Wakalah Programme established on 24 August 2023.

As at 30 September 2024, the proceeds raised from the issuance of Sukuk Wakalah have been fully utilised as follows:

Details of utilisation	Proceeds for Utilisation RM'000	Actual Utilisation RM'000	Balance Unutilised RM'000
Refinanced Group's borrowings	290,862	290,862	-
Defrayed fees, expenses, costs and all other amounts payable in relation to the Sukuk Wakalah Programme	1,325	1,325	-
Financing of Group's shariah-compliant working capital	100,813	100,813	-
<b>Total</b>	<b>393,000</b>	<b>393,000</b>	<b>-</b>



**B8 Borrowings and Debt Securities**

Details of Group's borrowings are as follows :-

	As at 30 September 2024 RM'000	As at 31 December 2023 RM'000
Current - unsecured	55,820	65,546
Non-current - unsecured	468,678	480,902
Total	524,498	546,448

**B9 Material litigation**

There was no material litigation up to 1 November 2024 (latest practicable date which is not earlier than 7 days from the date of issuance of this quarterly report).

**B10 Dividend**

The Directors do not recommend any interim dividend for the current quarter ended 30 September 2024. (2023:Nil)

**B11 Earnings per Share**

	Current year quarter 30/9/24	Current year to date 30/9/24
<b>a) Basic EPS</b>		
Net profit (RM'000)	15,595	47,562
Weighted average number of ordinary shares in issue ('000)		
-Balance b/f	961,942	961,942
	961,942	961,942
Basic EPS (sen)	1.62	4.94
<b>b) Dilutive EPS</b>		
Adjusted weighted average number of ordinary shares in issue ('000)		
-In issue during the period	961,942	961,942
	961,942	961,942
Dilutive EPS (sen)	1.62	4.94

**B12 Profit Before Tax**

	Current year quarter 30/9/24 RM '000	Current year to date 30/9/24 RM '000
<b>Operating profit is arrived at after charging / (crediting):</b>		
Depreciation of property, plant and equipment	9,831	30,129
Finance costs	6,968	20,756
Net impairment of inventories	2,915	6,317
Net foreign exchange loss	131	642
Interest income	(1,445)	(4,530)
Gain on disposal of PPE	(373)	(395)

Other than the above, there were no other material impairment of assets nor gain or loss on derivatives for the current quarter and current period ended 30 September 2024.

**B13 Authorisation for issue**

The interim financial statements were authorised for issue by the Board of Directors in accordance with a resolution of the directors on 8 November 2024.

By Order of the Board

Ibrahim Hussin Salleh  
Secretary  
License No.: LS 0009121  
SSM Practising Certificate No.: 201908001032  
Kuala Lumpur  
8 November 2024